Nurix Therapeutics, Inc. (NRIX)

Revenue by Segment

Financials in millions USD. Fiscal year is December - November.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Nov 30, 2025	Nov 30, 2024	Nov 30, 2023	Nov 30, 2022	Nov 30, 2021	Nov 30, 2020	Nov 30, 2019	Nov 30, 2018
Pharmaceuticals	83.98M	54.55M	76.99M	38.63M	29.75M
Pharmaceuticals Growth	53.95%	-29.15%	99.31%	29.84%	66.95%
Total	83.98M	54.55M	76.99M	38.63M	29.75M
Total Growth	53.95%	-29.15%	99.31%	29.84%	66.95%

Revenue by Geography

Financials in millions USD. Fiscal year is December - November.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Nov 30, 2025	Nov 30, 2024	Nov 30, 2023	Nov 30, 2022	Nov 30, 2021	Nov 30, 2020	Nov 30, 2019	Nov 30, 2018
United States	83.98M	54.55M	76.99M	38.63M	29.75M
United States Growth	53.95%	-29.15%	99.31%	29.84%	66.95%
Total	83.98M	54.55M	76.99M	38.63M	29.75M
Total Growth	53.95%	-29.15%	99.31%	29.84%	66.95%

Data Source: S&P Global Market Intelligence Last updated: Feb 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 28, 2026

Data Sources Report a data error